MedPath

Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus

Phase 4
Conditions
Type II Diabetes Mellitus
Interventions
Procedure: sleeve gastrectomy
Procedure: gastric bypass
Registration Number
NCT00540462
Lead Sponsor
Min-Sheng General Hospital
Brief Summary

Although intensive medical treatment of diabetes has clearly been demonstrated to be worthwhile, it has not been a total success in diabetes treatment for a variety of reasons including lack of response to medication. Diabetes has been well demonstrated as a co-morbidity illness of obesity patients. In observation, with exclusion stomach and duodenum of bariatric surgery (gastric bypass), most morbidly obese patients (about 80%) with diabetes had a significant improved of sugar control. Base of this observation, we will try to find out the role surgical intervention (gastric bypass \& sleeve gastrectomy) in obese-related diabetes.

Detailed Description

In observation, with exclusion stomach and duodenum of bariatric surgery (gastric bypass), most morbidly obese patients (about 80%) with diabetes had a significant improved of sugar control. Base on this observation, we will try to find out the role surgical intervention (gastric bypass and sleeve gastrectomy) in obese-related diabetes. With restriction of stomach volume and with or without duodenal exclusion, this randomized trials will find out the role of duodenal exclusion and the role of Ghrenin in obese-related type II DM patients. The initial observation of previous morbidly obese patients with type II DM, the DM seems a chronic disease which could be treated or controlled by surgical intervention, that's what we try to know more.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Patient with diagnosis of T2DM for at least 6 months
  • Mild to moderate obesity status(BMI 27 - 35 )
  • Age : 30 - 60 year-old
  • HbA1C > 8 %
Exclusion Criteria
  • With co-morbidity illness of cardiovascular system
  • DM related nephropathy (Cre >2.0 mg/dl)
  • Pulmonary embolism or uncontrolled coagulopathy in 6 months
  • HBV or HCV hepatitis or liver cirrhosis, inflammatory colon disease, Cushing syndrome
  • s/p organ transplantation
  • Previously Bariatric surgery, gastrointestinal surgery, or abdominal sepsis
  • Alcoholic or drug abuser
  • Psychological disease.
  • HIV or TB patient

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
3sleeve gastrectomySugical Group with Sleeve gastrectomy
2gastric bypassSurgical Group with gastric bypass
Primary Outcome Measures
NameTimeMethod
Measure sugar levels, HbA1c levels, and medication needed. OGTT, MGTT.1st, 2nd, 3rd, 4th, 5th, 6th, 9th, 12th months
Secondary Outcome Measures
NameTimeMethod
Comparing the DM controls between Medical and Surgical treatment In surgery groups, compare the bypass surgery and sleeve gastrectomy1 yr

Trial Locations

Locations (1)

MinSheng Genral Hospital

🇨🇳

Taoyuan, Taiwan

© Copyright 2025. All Rights Reserved by MedPath